Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Shares of Apple and Dell Technologies rise sharply after the Trump administration exempts smartphones, computers, memory ...

GSK's (GSK) stock rises as the company's Arexvy shot could see expanded CDC recommendations for RSV protection in at-risk ...

Goldman Sachs made significant rating changes across its U.S. biopharma coverage on Tuesday, upgrading the likes of Eli Lilly ...

Goldman Sachs downgraded Pfizer (PFE) to Neutral from Buy with a price target of $25, down from $32, after assuming coverage of the name. The ...

Earnings season kicks off in earnest with big banks continuing to report along with Netflix.

Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (LSE:0Q1N) from Buy to Neutral. As of April 2, 2025, the average one-year price target for Pfizer is 31.00 ...

Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (SNSE:PFE) from Buy to Neutral. There are 4,005 funds or institutions reporting positions in Pfizer.

Pfizer Inc (NYSE:PFE) shares are moving lower Wednesday alongside several pharmaceutical giants after President Donald Trump ...

Pfizer has ended development of danuglipron, an oral GLP-1 drug for weight management, citing clinical data and regulatory input.

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer (PFE – Research Report), with a price target ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...